Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 2, 2013, Pages 181-187

  Weaver, Kathryn E ^a   Camacho, Fabian ^b   Hwang, Wenke ^b   Anderson, Roger ^b   Kimmick, Gretchen ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adherence; adjuvant hormonal therapy; breast cancer; recurrence; survival

Indexed keywords

AMITRIPTYLINE; ANASTROZOLE; CELECOXIB; CIMETIDINE; CITALOPRAM; ESCITALOPRAM; EXEMESTANE; FLUOXETINE; LETROZOLE; LEVOMEPROMAZINE; METOCLOPRAMIDE; MIRTAZAPINE; PAROXETINE; PROPRANOLOL; SERTRALINE; TAMOXIFEN; TIMOLOL; VENLAFAXINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ETHNICITY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MEDICAID; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POVERTY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES;

EID: 84876112968     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182436ec1     Document Type: Article

References (57)

1. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-1717.
2. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
3. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
4. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
5. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
6. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138-5147.
7. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anas-trozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-462.
8. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
9. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
10. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619-629.
11. Grunfeld EA, Hunter MS, Sikka P, et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97-102.
12. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56-66.
13. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309-3315.
14. Murthy V, Bharia G, Sarin R. Tamoxifen non-compliance: does it matter? Lancet Oncol. 2002;3:654.
15. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322-328.
16. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189-1197.
17. Lash T, Fox M, Westrup J, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215-220.
18. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549-555.
19. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602-606.
20. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556-562.
21. van Herk-Sukel M, van de Poll-Franse L, Voogd A, et al. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5-years: a population-based analysis. Breast Cancer Res Treat. 2010;122:843-851.
22. Dezentje VO, van Blijderveen NJC, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28:2423-2429.
23. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99:1763-1768.
24. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2007;83:160-166.
25. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30-39.
26. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010; 340:c693.
27. Ahern TP, Pedersen L, Cronin-Fenton DP, et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev. 2009;18:2562-2564.
28. Thompson A, Johnson A, Quinlan P, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125:279-287.
29. Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27:3445-3451.
30. Kimmick G, Camacho F, Foley KL, et al. Racial differences in patterns of care among medicaid-enrolled breast cancer patients. J Oncol Pract. 2006;2:205-213.
31. Kimmick GG, Camacho F, Balkrishnan R, et al. Patterns of care among breast cancer patients with financial need: information from a Medicaid-claims and tumor registry linked database. J Clin Oncol. 2005;23:537S.
32. Anderson RT, Kimmick GG, Camacho F, et al. Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care. 2008;14:644-652.
33. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
34. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814-823.
35. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
36. Jean-Baptiste R, Gebhard IK (eds.). Series IV: Cancer Case Ascertainment. Procedure guidelines for cancer registries. Springfield, IL: North American Association of Central Cancer Registries; 2002.
37. Johnson CH, Adamo M. SEER Program Coding and Staging Manual 2007. Bethesda, MD: National Cancer Institute; 2007.
38. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49:1429-1433.
39. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: the completeness of death reporting at older ages. Soc Secur Bull. 2001;64:45-51.
40. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health. 2009;18:883-893.
41. Foley K, Kimmick G, Camacho F, et al. Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy. Breast Cancer Res Treat. 2007;101:207-214.
42. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128-1143.
43. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre-and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol. 2008;26:3958-3964.
44. Ogunleye A, Holmes M. Physical activity and breast cancer survival. Breast Cancer Research. 2009;11:106.
45. Li CI, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol. 2009;27:5312-5318.
46. Holmes MD, Murin S, Chen WY, et al. Smoking and survival after breast cancer diagnosis. Int J Cancer. 2007;120:2672-2677.
47. Dunnwald L, Rossing M, Li C. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
48. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254-1261.
49. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
50. Kwan M, Kushi L, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31.
51. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452-8458.
52. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11:126-135.
53. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Rev Cancer. 2009;9:576-586.
54. Fabian C, Sternson L, El-serafi M, et al. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer. 1981;48:876-882.
55. Buzdar AU, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006-2016.
56. Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112: 2456-2466
57. The Early Breast Cancer Trialists' Collaborative Group. Tamox-ifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.